Home
Superbugs & Superdrugs - A Focus on Antibacterials
4 March - 5 March 2013
Superbugs & Superdrugs - A Focus on Antibacterials

SAE Media Group are proud to present their 15th Annual Superbugs and Superdrugs Conference. This exciting event will bring together industry leaders from big pharma, biotechs, regulatory agencies and academia to discuss the latest in the antibacterial market. This unique conference will present attendees with a complete view into the latest in combating multi-drug resistance, diagnostics and new focus on vaccine development for the prevention of nosocomial bacterial infections.

This year’s event will also discuss the latest developments in natural product advancements and strategies to building public-private partnerships to overcome antibacterial resistance.

With senior industry representatives presenting on their own experiences and referring to case studies, success stories and failures, this event promises to be a unique forum for problem-solving debate and idea-sharing discussion.

FEATURED SPEAKERS

Joseph Larsen

Joseph Larsen

Chief Broad Spectrum Antimicrobials BSA Program, Biomedical Advanced Research and Development Authority
Jutta Heim

Jutta Heim

Professor of Biotechnology chief scientific officer, Evolva SA
Line Matthiessen

Line Matthiessen

Head of Infectious Diseases and Public Health Unit, European Commision
Pierre  Raboisson

Pierre Raboisson

Head of Medicinal Chemistry, Johnson and Johnson Pharmaceutical Research and Development
William Weiss

William Weiss

Director of Pre-Clinical Services, University of North Texas Health Science Center

Adrijana Vinter

Business Development Officer, Fidelta
Adrijana Vinter

Andrew Mearns Spragg

Chief Technical Officer, Aquapharm Biodiscovery
Andrew Mearns Spragg

Anthony Coates

Professor, St George's, University of London
Anthony Coates

Barry Hafkin

Chief Medical Officer, Affinium Pharmaceuticals
Barry Hafkin

Cedric Couturier

Head of Laboratory, Sanofi
Cedric Couturier

Christian Felter

Associate Director, Medical Affairs, Astellas Pharma Europe
Christian Felter

Erin Duffy

Chief Scientific Officer, Rib-X Pharmaceuticals
Erin Duffy

Jerome Guillemont

Scientific Director - Fellow, Johnson & Johnson
Jerome Guillemont

Joseph Larsen

Chief Broad Spectrum Antimicrobials BSA Program, Biomedical Advanced Research and Development Authority
Joseph Larsen

Jutta Heim

Professor of Biotechnology chief scientific officer, Evolva SA
Jutta Heim

Line Matthiessen

Head of Infectious Diseases and Public Health Unit, European Commision
Line Matthiessen

Malcolm Page

Head of Biology, Basilea Pharmaceutica Ltd
Malcolm Page

Neil Ryder

Executive Director, Infectious Diseases, Novartis Institutes for Biomedical Research Inc.
Neil Ryder

Peter Warn

Chief Scientific Officer, Euprotec
Peter Warn

Pierre Raboisson

Head of Medicinal Chemistry, Johnson and Johnson Pharmaceutical Research and Development
Pierre  Raboisson

Richard Bax

Senior Partner, TranScrip Partners
Richard Bax

Richard Bergstrom

Director General, EFPIA
Richard Bergstrom

Ursula Theuretzbacher

Founder, Center For Anti-Infective Agents
Ursula Theuretzbacher

William Weiss

Director of Pre-Clinical Services, University of North Texas Health Science Center
William Weiss

Our 2013 event is currently in production - if you are interested in speaking at this event, please contact the producer now.

If you are interested in finding out about sponsorship opportunities at this event, please contact our sponsorship department now.

Conference agenda

clock

8:30

Registration & Coffee

clock

9:00

Chairman's Opening Remarks

Richard Bax

Richard Bax, Senior Partner, TranScrip Partners

clock

9:10

The war you cannot win - but survive: how the pharma industry is mobilising to get the pipeline going

Richard Bergstrom

Richard Bergstrom, Director General, EFPIA

  • Pooling resources in public-private partnerships with the European Commision (IMI and Horizon 2020)
  • Towards reasonable and predicatble regulatory requirements
  • Bringing back old compound: what incentives are used?
  • How to preserve new antibiotics? A global compact for controlled use?
  • clock

    9:50

    Update on current R&D and the Regulatory Environment

    Richard Bax

    Richard Bax, Senior Partner, TranScrip Partners

  • Big and little pharma activity and progress
  • Report on REACT, BSAC, IDSA, Barda FP7 EU and Innovative Medicines Initiative
  • A developers view on the EMA workshop on the development of new antibacterial medicines - October 2012
  • Prospects for the future
  • clock

    10:10

    Round Table Discussion

    Richard Bax

    Richard Bax, Senior Partner, TranScrip Partners

    Richard Bergstrom

    Richard Bergstrom, Director General, EFPIA

    Ursula Theuretzbacher

    Ursula Theuretzbacher, Founder, Center For Anti-Infective Agents

    Line Matthiessen

    Line Matthiessen, Head of Infectious Diseases and Public Health Unit, European Commision

    clock

    10:45

    Morning Coffee

    clock

    11:00

    The use of isogenic strains in antimicrobial drug discovery

    Peter Warn

    Peter Warn, Chief Scientific Officer, Euprotec

  • Highly characterised isogenic strains
  • Uses of isogenic strains in vivo systems
  • PK/PD with isogenic strains
  • clock

    11:40

    An update on current issues and progress in C. difficile disease (CDAD)

    William Weiss

    William Weiss, Director of Pre-Clinical Services, University of North Texas Health Science Center

  • A brief history and review
  • The changing epidemiology and resistance development in CDAD
  • Transmission, Virulence factors and clinical manifestations
  • Surveillance, diagnosis and clinical testing
  • Prevention, emerging therapies and potential for efficacy
  • clock

    12:20

    Networking Lunch

    clock

    13:20

    Case study: development candidate BAL30072

    Malcolm Page

    Malcolm Page, Head of Biology, Basilea Pharmaceutica Ltd

    • .Activity of BAL30072 against multi-drug resistant Gram-negative bacteria
    • .Activity of BAL30072 against Burkholderia pseudomallei and B. mallei
    • .Combined effects of BAL30072 and carbapenems in vitro
    • .Enhanced activity of BAL30072 and meropenem in animal infection models

    clock

    14:00

    The design of a novel class of antibiotics for the treatment of highly resistant gram-negatives

    Erin Duffy

    Erin Duffy, Chief Scientific Officer, Rib-X Pharmaceuticals

    An exploration of the process to engineer new antibiotics for the worst bacteria
    Overcoming known resistance mechanisms
    Achieving the desired safety window 

    clock

    14:40

    Armeniaspiroles : new class of antibacterials

    Cedric Couturier

    Cedric Couturier, Head of Laboratory, Sanofi

    • Gram-positive bacterial pathogens
    • Fermentation, structure isolation and characterization 
    • Total synthesis
    • Natural products

    clock

    15:20

    Afternoon Tea

    clock

    15:40

    Discovery of Discovery and development of Simeprevir (TMC435) and TMC647055, two novel direct antiviral agents targeting the Hepatitis C Virus

    Pierre  Raboisson

    Pierre Raboisson, Head of Medicinal Chemistry, Johnson and Johnson Pharmaceutical Research and Development

     

  • HepatitisC virus (HCV)-encoded NS3/4A protease and NS5B polymerase are essentail for viral replication and represent two attractive targets for therapeutic intervention in HCV-infected patients
  • Both NS3/4A protease and NS5B non-nucleoside inhibitors are able to decrease HCV viremia, either as monotherapy or in addition to the current standard of care therapy
  • Simeprevir (TMC435) and TMC647055 are two potent and selective inhibitors of HCV replication in genotype 1b replicon cells with EC50 values of 8 nM and 82 nM, respectively
  • Combination of these two drug candidates in an interferon-free setting is currently under investigation in the clinic
  • clock

    16:20

    GC-072: A novel resistance-breaking oxoquinolizine

    Jutta Heim

    Jutta Heim, Professor of Biotechnology chief scientific officer, Evolva SA

    • Novel oxoquinolizine
    • Broad-spectrum and potent topisomerase inhibitor
    • Different binding site than quinolones
    • Excellent in vitro coverage of Gram-positive and Gramnegative MDR pathogens
    • Favorable PK and initial Tox profile
    • Active in in vivo infection models, oral and IV

    clock

    17:00

    Antibacterial Developments in Tuberculosis Research

    Anthony Coates

    Anthony Coates, Professor, St George's, University of London

  • New models are needed for antibacterial development in TB
  • Novel in vitro models which mimic TB persister bacteria
  • New murine models which are more similar to human tuberculosis than current models
  • clock

    17:40

    Chairman’s Closing Remarks and Close of Day One

    clock

    8:30

    Registration & Coffee

    clock

    9:00

    Chairman's Opening Remarks

    William Weiss

    William Weiss, Director of Pre-Clinical Services, University of North Texas Health Science Center

    clock

    9:10

    Discovery of Bedaquiline (TMC207), a new candidate for the treatment of tuberculosis

    Jerome Guillemont

    Jerome Guillemont, Scientific Director - Fellow, Johnson & Johnson

  • Short introduction on the disease
  • A look into the current pipeline
  • History of DARQs (diarylquinoline class)/SAR
  • TMC207, properties / spectrum of activity/ in vivo efficacy/ MOA
  • clock

    9:50

    Invasive Fungal Infections: New Approaches

    Christian Felter

    Christian Felter, Associate Director, Medical Affairs, Astellas Pharma Europe

  • Review the evolving epidemiology of invasive fungal infections
  • The current treatment landscape
  • What's next?
  • clock

    10:30

    Morning Coffee

    clock

    11:00

    The other superbugs: fungal pathogens and progeress in antifungal research

    Neil Ryder

    Neil Ryder, Executive Director, Infectious Diseases, Novartis Institutes for Biomedical Research Inc.

  • The burden of funal disease; old , new and emerging pathogens
  • The threat of fungal drug resistance
  • Recent advances in antifungal drugs
  • Fungi in the context of other infectious diseases
  • Trends and outlook for novel therapies
  • clock

    11:40

    Clinical Evidence for FabI Antibiotics

    Barry Hafkin

    Barry Hafkin, Chief Medical Officer, Affinium Pharmaceuticals

  • Scientific rationale for FabI inhibors, a new mechanism of action drug class
  • Clinical proof of concept in Phase 2:  safety and efficacy
  • Rationale use of a Staph specific spectrum antibiotic in clinical practice
  • clock

    12:20

    Networking Lunch

    clock

    13:20

    The design and synthesis of novel antibiotic macrolones

    Adrijana Vinter

    Adrijana Vinter, Business Development Officer, Fidelta

  • SAR analysis of resistant phenotypes
  • Design of molecules to overcome resistance
  • Synthetic methodology
  • Results
  • clock

    13:50

    Partnering and working with BARDA

    Joseph Larsen

    Joseph Larsen, Chief Broad Spectrum Antimicrobials BSA Program, Biomedical Advanced Research and Development Authority

  • Background on BARDA
  • Strategic emphasis of BARDA in addressing antimicrobial resistance
  • Examples of current partnerships
  • How to engage and work effectively with BARDA
  • clock

    14:30

    New partnerships to combat antimicrobial resistance

    Line Matthiessen

    Line Matthiessen, Head of Infectious Diseases and Public Health Unit, European Commision

  • Meeting the challenges in implementing the European Commission's Action Plan on antimicrobial resistance
  • Partnerships with industry on antimicrobial resistance
  • Partnership amnog countries on antimicrobial resistance
  • The vision on futrue research under Horizon 2020
  • clock

    15:10

    Afternoon Tea

    clock

    15:40

    Publicly funded antibacterial drug development in Europe

    Ursula Theuretzbacher

    Ursula Theuretzbacher, Founder, Center For Anti-Infective Agents

    • In an era of increasing antimicrobial resistance and dwindling antibiotic resources, publicly funded drug development projects intend to give much needed impulses to bridge the bottlenecks between discovery and early development and thus, for advancing promising antibacterial R&D concepts into the clinics
    • “Redevelopment” of off-patent antibiotics in academic settings funded by government grants is the only currently viable way forward
    • The urgent need for efficient and innovative concepts for developing novel as well as “redeveloping” old antibiotics demands concerted action based on private and public funding

    clock

    16:20

    Novel antibiotics from marine microorganisms

    Andrew Mearns Spragg

    Andrew Mearns Spragg, Chief Technical Officer, Aquapharm Biodiscovery

  • The need for novel antibiotics and novel mechanisms of action
  • Diverse chemistry from marine mircoorganisms
  • Examples of novel antibiotics from marine sources
  • Approaches to optimize discovery of natural product chemistry
  • clock

    17:00

    Chairman’s Closing Remarks and Close of Day Three


    Professor
    St George's, University of London
    Chief Medical Officer
    Affinium Pharmaceuticals
    Head of Laboratory
    Sanofi
    Associate Director, Medical Affairs
    Astellas Pharma Europe
    Chief Scientific Officer
    Rib-X Pharmaceuticals
    Scientific Director - Fellow
    Johnson & Johnson
    Chief Broad Spectrum Antimicrobials BSA Program
    Biomedical Advanced Research and Development Authority
    Professor of Biotechnology chief scientific officer
    Evolva SA
    Head of Infectious Diseases and Public Health Unit
    European Commision
    Head of Biology
    Basilea Pharmaceutica Ltd
    Executive Director, Infectious Diseases
    Novartis Institutes for Biomedical Research Inc.
    Chief Scientific Officer
    Euprotec
    Head of Medicinal Chemistry
    Johnson and Johnson Pharmaceutical Research and Development
    Director General
    EFPIA
    Founder
    Center For Anti-Infective Agents
    Director of Pre-Clinical Services
    University of North Texas Health Science Center
    Business Development Officer
    Fidelta
    Chief Technical Officer
    Aquapharm Biodiscovery
    Senior Partner
    TranScrip Partners

    Copthorne Tara Hotel

    Scarsdale Place
    Kensington
    London W8 5SR
    United Kingdom

    Copthorne Tara Hotel

    The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

    The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

     

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download

    Title


    Description

    Download

    Title


    Description


    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SAE Media Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@saemediagroup.com

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SAE Media Group

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SAE Media Group , Ground Floor, India House, 45 Curlew Street, London, SE1 2ND, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smgconferences.com Email: events@saemediagroup.com
    Registered in England - SMi Group Ltd trading as SAE Media Group




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.

    Thank you for visiting our event

    If you would like to receive further information about our events, please fill out the information below.

    By ticking above you are consenting to receive information by email from SAE Media Group.
    Full details of our privacy policy can be found here https://www.smgconferences.com/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data@smgconferences.com.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smgconferences.com/opt-out

    Fill in your details to download the brochure

    By submitting this form you agree to our privacy policy and consent to receiving communications, you may opt out at any time.